Certain studies reported data that precluded the use of WHO outcome definitions, and were not included for analysis.
Although baseline subject characteristics were reported in terms of HbA1c, certain studies reported end values in terms of glycated albumin, necessitating the use of SMDs in our analysis.
Certain studies reported the use of standardized CT density phantoms to correct the CT values of CBCT images for dose calculation [ 8– 10].
However, the reports are controversial with certain studies reporting a decrease [ 29, 30] or no change [ 31– 33] in cerebral GLUT-1 and SGLT-1 protein expression, and an increase [ 34] or unaltered [ 33] local cerebral glucose utilization.
Therefore, the extent to which comorbidity has an independent prognostic effect on mortality is challenged by certain studies reporting that the effect of comorbidity on survival is contingent upon patients' functional status and the severity of their comorbid conditions.
We included all major references that were cited where more than one reference was given and did not prioritize certain study reporting types.
The concern stems from certain epidemiology studies reporting an association, although particulars of endpoints and dosimetry are inconsistent across studies and several other studies show no such effects.
It is possible that certain interventional studies reported high readmission rates due to increased anxiety or even increased complications in patients using self-monitoring devices.
Certain previous studies reported that women were more inclined than men to look for social support [ 21, 25, 35, 44] and to benefit from social support when coping with stress [ 11, 38].
Although certain studies have reported high risk ratios, enthusiasm for these must be tempered by the small group size involved and the authors' reporting of a genotype-specific effect, rather than the allelic one commonly used.
